With NCI Grant, Librede Looks to Develop Nanopore-Based microRNA Diagnostic | GenomeWeb

NEW YORK (GenomeWeb) – Looking to expand beyond ion channel drug screening, Librede has begun work on developing its core artificial lipid bilayer technology for use in an automated nanopore-based platform for microRNA diagnostics.

With the support of a six-month, $224,000 grant from the National Cancer Institute, the company aims to develop a prototype system that can detect the small, non-coding RNAs cheaply and with off-the-shelf reagents, CEO Jason Poulos told GenomeWeb.

Once that work is complete, Librede aims to test its approach in clinical samples, he said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.